New Target Could Expand PARP Inhibitor Effectiveness
Researchers find that depleting the DKC1 protein sensitizes cancer cells to PARP inhibitors.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you believe new research on synthetic lethality will improve cancer treatment outcomes for more patients?
Scientists have identified a synthetic lethal interaction between PARP inhibitors and the dyskerin protein, known as DKC1. This discovery suggests a potential method to treat solid tumors that do not currently respond well to standard PARP inhibitor therapies.
Why it matters
PARP inhibitors are effective for BRCA mutant tumors, but many solid tumors are HR-proficient and resist these treatments. Targeting DKC1 may help extend the therapeutic reach of these drugs to a wider range of cancer patients.
A genome-wide CRISPR-Cas9 screen identified DKC1 as a target that, when depleted, causes chromatin remodeling that phenocopies HR deficiency. This loss impairs pseudouridylation of chromatin-associated RNAs and compromises BRCA1 recruitment.
The players
PARP inhibitors
These are a class of targeted cancer drugs that prevent tumor cells from repairing their own DNA.
DKC1
Also known as dyskerin, this protein is an RNA pseudouridine synthase that plays a role in chromatin structure and gene regulation.
The details
By depleting DKC1, researchers successfully sensitized HR-proficient cancer cells to PARP inhibitors in both in vitro and xenograft models. This process works by reducing chromatin accessibility and inhibiting the recruitment of proteins like RAD21.
Timeline
The findings were published on October 31, 2026.
The Big Picture
This finding marks a shift in cancer research by potentially overcoming the limitations of PARP inhibitors in HR-proficient solid tumors. It builds upon the established success of existing therapies to address resistance mechanisms in a broader patient population.
This research provides a new pathway that could eventually lead to expanded treatment options for patients with HR-proficient solid tumors. It does not currently change existing medical practices as the findings are limited to preclinical research models.
The takeaway
Targeting DKC1 represents a promising strategy to overcome drug resistance in certain cancer types. Patients and providers should look for further clinical trials to determine if these laboratory results can be successfully replicated in humans.
Further reading
Learn more about the latest developments in the field at the Cancer research hub.
More information
Read the complete peer-reviewed research article for detailed findings.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new research on synthetic lethality will improve cancer treatment outcomes for more patients?
